Switzerland· 53563001
Wellvone, Suspension
A atovaquone product, registered in Switzerland by GlaxoSmithKline AG and dispensed under Swissmedic category A. The same ATC class is registered in 11 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Atovaquone is registered in 11 of 19 countries.
Countries holding a registration under ATC P01AX06 (atovaquone), each read from that country’s own register.
- This record: Switzerland
- 5 of them publish a price we can compare per daily dose
Atovaquone · ATC P01AX06
11 / 19 countries
- Belgiumprice
- Canada
- Denmark
- Franceprice
- Germany
- Netherlands
- Norwayprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
- Manufacturer
- GlaxoSmithKline AG
- Country
- Switzerland (CH)
- ATC code
- P01AX06
- ATC class
- Atovaquone
- Defined daily dose
- 1.5 g, O
- Swissmedic category
- A
- Reimbursed
- No
- Last checked
- June 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
182 interactions on record for atovaquone.
Graded by severity as the source publishes them — 8 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Atovaquone · interactions on record
182 records
- 8 severe
- 32 moderate
- 4 minor
- 133 info
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- EfavirenzJ05AG03severe
- PexidartinibL01EX15severe
5 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under P01AX06
Atovaquone, as other registers publish it.
- DenmarkAtovaquon "Nordic Prime"Nordic Prime ApS
- GermanyAtovaquon GlenmarkGlenmark Arzneimittel Gmbh
- NetherlandsAtovaquon Glenmark 750 mg/5 ml suspensie voor oraal gebruikGlenmark Arzneimittel GmbH
- United StatesatovaquoneGlenmark Pharmaceuticals Inc., USA
- United StatesAtovaquoneCamber Pharmaceuticals, Inc.
- United StatesAtovaquonePAI Holdings, LLC dba PAI Pharma
- United StatesAtovaquoneA2A Integrated Pharmaceuticals, LLC
- United StatesAtovaquoneATLANTIC BIOLOGICALS CORP.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a912f50d-d7f7-4166-ab65-b593d266f527 GET /v1/drugs/a912f50d-d7f7-4166-ab65-b593d266f527?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Synthetika"
}See everything about atovaquone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.